Vadadustat - Akebia Therapeutics

Drug Profile

Vadadustat - Akebia Therapeutics

Alternative Names: AKB-6548; MT 6548; PG-1016548

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procter & Gamble
  • Developer Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation
  • Class Antianaemics; Chlorophenols; Pyridines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 08 Nov 2017 Akebia Therapeutics plans the TRILO2GY phase III trial for Anaemia in USA in 2017 or early 2018 (NCT03242967)
  • 01 Nov 2017 Phase-III clinical trials in Anaemia in Japan (PO) (NCT03329196)
  • 26 Sep 2017 Akebia Therapeutics in collaboration with Mitsubishi Tanabe Pharma Corporation intends to initiate a phase III development programme for Anaemia (In non-dialysis patients) in Japan by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top